Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago. These ...

Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 ...

The Biotechnology Master of Science degree program provides students with advanced coursework in biotechnical and biomolecular sciences. Graduates are prepared for positions in research, and ...

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...

The BioXplorer 400 has been fitted with four bioreactors along with working volumes of up to 400 mL. It is an ideal tool for parallel bioprocess optimization. The highly configurable nature of ...

5 analysts have expressed a variety of opinions on Vir Biotechnology (NASDAQ:VIR) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...